These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 3880962)

  • 1. Cellular interactions in marrow-grafted patients. III. Normal interleukin 1 and defective interleukin 2 production in short-term patients and in those with chronic graft-versus-host disease.
    Brkic S; Tsoi MS; Mori T; Lachman L; Gillis S; Thomas ED; Storb R
    Transplantation; 1985 Jan; 39(1):30-5. PubMed ID: 3880962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular interactions in marrow-grafted patients. II. Normal monocyte antigen-presenting and defective T-cell-proliferative functions early after grafting and during chronic graft-versus-host disease.
    Tsoi MS; Dobbs S; Brkic S; Ramberg R; Thomas ED; Storb R
    Transplantation; 1984 Jun; 37(6):556-61. PubMed ID: 6233768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ineffective cellular interaction and interleukin 2 deficiency causing T cell defects in human allogeneic marrow recipients early after grafting and in those with chronic graft-versus-host disease.
    Tsoi MS; Mori T; Brkic S; Dobbs S; Gillis S; Santos E; Thomas ED; Storb R
    Transplant Proc; 1984 Dec; 16(6):1470-2. PubMed ID: 6390848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serial evaluation of lymphocyte function in bone marrow-grafted patients.
    D'Andrea AD; Bayever E; Haines KM; Wilmott RW; Polin RA; August CS; Douglas SD
    Diagn Immunol; 1986; 4(6):281-7. PubMed ID: 3102148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular interactions in marrow-grafted patients. I. Impairment of cell-mediated lympholysis associated with graft-vs-host disease and the effect of interleukin 2.
    Mori T; Tsoi MS; Gillis S; Santos E; Thomas ED; Storb R
    J Immunol; 1983 Feb; 130(2):712-6. PubMed ID: 6217250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of prostaglandin E2 restores defective lymphocyte proliferation and cell-mediated lympholysis in recipients after allogeneic marrow grafting.
    Klingemann HG; Tsoi MS; Storb R
    Blood; 1986 Jul; 68(1):102-7. PubMed ID: 2941083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies on cellular inhibition and serum-blocking factors in 28 human patients given marrow grafts from HLA identical siblings.
    Tsoi MS; Storb R; Weiden PL; Thomas ED
    J Immunol; 1977 May; 118(5):1799-805. PubMed ID: 16061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of interleukin-12 in the development of acute graft-versus-host disease in bone marrow transplant patients.
    Yabe M; Yabe H; Hattori K; Shimizu T; Matsumoto M; Morimoto T; Yasuda Y; Inoue H; Kato S; Nishimura T
    Bone Marrow Transplant; 1999 Jul; 24(1):29-34. PubMed ID: 10435731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-producer interleukin-2 genotype increases risk for acute graft-versus-host disease after unrelated donor bone marrow transplantation.
    MacMillan ML; Radloff GA; Kiffmeyer WR; DeFor TE; Weisdorf DJ; Davies SM
    Transplantation; 2003 Dec; 76(12):1758-62. PubMed ID: 14688528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokine gene expression by concanavalin A-stimulated peripheral mononuclear cells after bone marrow transplantation: an indicator of immunological abnormality due to chronic graft-versus-host disease.
    Tanaka J; Imamura M; Kasai M; Zhu X; Kobayashi S; Imai K; Hashino S; Higa T; Sakurada K; Miyazaki T
    Bone Marrow Transplant; 1994 Nov; 14(5):695-701. PubMed ID: 7889002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe hematopoietic alterations in vitro, in bone marrow transplant recipients who develop graft-versus-host disease.
    Martínez-Jaramillo G; Gómez-Morales E; Sánchez-Valle E; Mayani H
    J Hematother Stem Cell Res; 2001 Jun; 10(3):347-54. PubMed ID: 11454310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proliferation of peripheral lymphocytes to interleukin-2 and interleukin-4 after marrow transplantation.
    Klingemann HG; Kohn FR; Phillips GL
    Eur Cytokine Netw; 1991; 2(2):131-6. PubMed ID: 1813016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibronectin restores defective in vitro proliferation of patients' lymphocytes after marrow grafting.
    Klingemann HG; Tsoi MS; Storb R
    Transplantation; 1986 Oct; 42(4):412-7. PubMed ID: 2945302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of CD8 cytolytic T cells early after autologous or allogeneic bone marrow transplantation.
    Charmot D; Ragueneau M; Olive D; Maraninchi D; Mawas C
    Bone Marrow Transplant; 1987 Aug; 2(2):183-94. PubMed ID: 2901879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alloreactivity and the predictive value of anti-recipient specific interleukin 2 producing helper T lymphocyte precursor frequencies for alloreactivity after bone marrow transplantation.
    Russell CA
    Dan Med Bull; 2002 May; 49(2):89-108. PubMed ID: 12064093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Graft-versus-host disease after marrow transplantation.
    Storb R
    Prog Clin Biol Res; 1986; 224():139-57. PubMed ID: 3540990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetics of restoration of interferon production after bone marrow transplantation in man.
    Koscielniak E; Bruchelt G; Treuner J; Uchanska-Ziegler B; Dopfer R; Vallbracht A; Niethammer D
    Bone Marrow Transplant; 1987 Apr; 1(4):379-87. PubMed ID: 2458787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
    Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
    J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Significance of interleukin 10 for acute graft versus host disease in children and adolescents after allogenic bone marrow transplantation].
    Körholz D; Hempel L; Packeisen J; Kunst D; Zintl F; Burdach S
    Klin Padiatr; 1996; 208(4):141-4. PubMed ID: 8926680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Significance of donors treatment with combination of recombinant human interleukin-11 and recombinant human granulocyte-colony stimulating factor in reduction of incidence of lethal grafts versus host disease after allogeneic bone marrow transplantation].
    Zhao J; Zhao XY; Huang XJ
    Zhonghua Yi Xue Za Zhi; 2005 Sep; 85(35):2497-502. PubMed ID: 16321278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.